Literature DB >> 29297516

Erratum: Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933-946.

.   

Abstract

[This corrects the article DOI: 10.1182/bloodadvances.2016004176.].

Entities:  

Year:  2017        PMID： 29297516      PMCID： PMC5728476          DOI： 10.1182/bloodadvances.2017011148

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  3 in total

Review 1.  Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively.

Authors:  Carol Moreno; Cecilia Muñoz; María José Terol; José-Ángel Hernández-Rivas; Miguel Villanueva
Journal:  J Exp Clin Cancer Res       Date:  2021-10-15

2.  Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.

Authors:  Haijiao Zhang; Yusuke Nakauchi; Thomas Köhnke; Melissa Stafford; Daniel Bottomly; Rozario Thomas; Beth Wilmot; Shannon K McWeeney; Ravindra Majeti; Jeffrey W Tyner
Journal:  Nat Cancer       Date:  2020-08-18

3.  [Resistance mechanisms and treatment strategies of Venetoclax in chronic lymphocytic leukemia].

Authors:  H S Zou; S H Yi; L G Qiu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-09-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.